Loading
Recurrent / Lorlatinib / Ramucirumab · Phase 1/2 Trial
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registry record describing an active Phase 1/2 study of lorlatinib plus ramucirumab in metastatic ALK-rearranged NSCLC. No results are posted in this registry entry; the study is designed to establish a maximum tolerated dose in Phase 1, then evaluate progression-free survival in Phase 2 using that dose.
Phase 1/2, Interventional, Sequential, Open label, Treatment purpose. Non Small Cell Lung Cancer, Metastatic, Recurrent; age from 19 Years. Intervention: Lorlatinib and ramucirumab. n = 9. 6 sites: United States.
This is a clinical trial registry record describing an active Phase 1/2 study of lorlatinib plus ramucirumab in metastatic ALK-rearranged NSCLC. No results are posted in this registry entry; the study is designed to establish a maximum tolerated dose in Phase 1, then evaluate progression-free survival in Phase 2 using that dose.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should not infer any efficacy or safety data from this registry record. Results of Phase 1 dose escalation and Phase 2 efficacy are not yet reported and are needed before any clinical decision-making.
Early-phase dose-finding study (Phase 1/2) with very small enrollment (9 participants) and no results reported; designed to establish safety and MTD before efficacy testing.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should not infer any efficacy or safety data from this registry record. Results of Phase 1 dose escalation and Phase 2 efficacy are not yet reported and are needed before any clinical decision-making.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06007937). This is a study registration, not published results. Lead sponsor: Memorial Sloan Kettering Cancer Center. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 9 participants (ACTUAL). Conditions: Non Small Cell Lung Cancer, Metastatic, Recurrent. Interventions: DRUG: Lorlatinib; DRUG: Ramucirumab. Primary outcome measures: Maximum tolerated dose (MTD) (Phase I) , 1 year; Progression-free survival (Phase II) , 12 months. Brief summary: This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or DNA sequences associated with a response to treatment with lorlatinib and ramucirumab.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.